Use our account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Food and Drug Administration

Food and Drug Administration

6 results

Filter Results By

Filter Applied. Clear All

Latest Posts

June 18, 2024 Written Testimony of Dr. Ingrid Skop on Interstate Travel for Abortion Written Testimony of Dr. Ingrid Skop on Interstate Travel for Abortion June 3, 2024 Abortion Reporting: Arkansas (2023) Abortion Reporting: Arkansas (2023) May 29, 2024 Abortion Reporting: West Virginia (2023) Abortion Reporting: West Virginia (2023)
Reset All Filters
6 results
Food and Drug Administration

Chemical Abortion: FDA Ignores ‘Inconvenient’ Science and Data Confirming Public Health Threat

The U.S. Food and Drug Administration (FDA) today announced plans to irresponsibly erode longstanding patient safeguards on the abortion pill, despite major U.S. and international research confirming that chemical abortion has led to a surge in emergency room visits and higher rates of complications.

charlotte-lozier-institute Charlotte Lozier Institute
December 16, 2021
ClosePlease login
Food and Drug Administration

Public Health Threat: Chemical Abortion Leads to Significantly Higher Rate of ER Visits

As the Food and Drug Administration (FDA) works toward a December 16 decision on chemical abortion safeguards, a groundbreaking new study from Charlotte Lozier Institute (CLI) shows that increased access to abortion pills creates a significant public health risk.

featured-image
Food and Drug Administration

FDA’s Race to Defend Women From Dangerous Drugs

Abortion advocates—seeking to exploit the COVID-19 crisis to advance unfettered access to abortion-inducing drugs—found a friend in federal court.  In mid-July, Judge Theodore D. Chuang issued a preliminary injunction prohibiting the Food and Drug Administration (FDA) from enforcing certain health and safety practices that abortion providers are required to follow when prescribing the only FDA-approved abortion drug regimen.

featured-image
Food and Drug Administration

News Release: Abortion Activist Sues FDA over Regulation of Dangerous Drugs 

Today Charlotte Lozier Institute released the following response to a lawsuit seeking to stop U.S. Food and Drug Administration enforcement of the regulation of dangerous abortion drugs shipped into the United States from overseas.

featured-image
Food and Drug Administration

Bicameral Congressional Letter Demands Transparency from FDA

Yesterday 75 members of Congress, led by Rep. Chris Smith of New Jersey and Sen. James Lankford of Oklahoma, sent a letter to the Commissioner of the Food and Drug Administration demanding answers to questions about the FDA’s surprise approval of relaxed protocols for the distribution of the abortion-inducing drug regimen known as Mifeprex.

Food and Drug Administration

Medication Abortion: FDA Guidelines and Personal Experience

Last week, the Food and Drug Administration (FDA) changed the regulations for RU-486, the “abortion pill,” allowing its use up to 70 days into pregnancy, three weeks past the previous guidelines. On the same day, Abby Johnson’s The Walls Are Talking: Former Abortion Clinic Workers Tell Their Stories, was officially released. One chapter in particular stood out as especially timely in regards to the news: “Medication Abortion.”

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image